China Factory PMI Seen Returning to Growth in June as AI Export Demand Supports Economy 
Canada Grants C$7 Million to Greenland Molybdenum Mine to Strengthen Critical Minerals Supply 
Asian Stocks Slip as US-Iran Ceasefire Hopes Lift Oil, Dollar Strength Persists 
Economic pessimism has set in – but there are reasons for Australians to be hopeful 
Gold Price Falls as Fed Rate Hike Fears and U.S.-Iran Tensions Weigh on Bullion 
China Expands Export Controls, Adds 20 Japanese Companies to Restricted List 
Asian Currencies Stay Range-Bound as Investors Eye China Data, RBNZ Outlook and U.S.-Iran Ceasefire 
Gold Price Ends Lower for Fourth Week Despite Rebound as Fed Rate Hike Bets Strengthen 
Asian Currencies Trade Mixed as Yen Hovers Near 40-Year Low, Dollar Holds Firm on Fed Outlook 
Oil Prices Rise as US-Iran Tensions Threaten Strait of Hormuz Oil Shipments 
US Stock Futures Rise as US-Iran Ceasefire Hopes Boost Market Sentiment 
China Sets 1.25% Overnight Reverse Repo Rate Below Market Expectations 
Oil Prices Rebound as Strait of Hormuz Tensions Return After Ship Attack Near Oman 
Morgan Stanley Sees Chinese Auto Market Recovery Gaining Momentum in Late Summer 
S&P Affirms Brazil’s BB Credit Rating with Stable Outlook Amid Fiscal Challenges 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
Roche CEO Urges FTC to Block Novo Nordisk's Acquisition of Catalent
Roche's CEO, Thomas Schinecker, has called on authorities to prevent Novo Nordisk’s controlling shareholder, Novo Holdings, from acquiring contract drug manufacturer Catalent. Schinecker voiced concerns about the potential negative impact on competition, particularly for smaller industry players. "While this doesn’t directly affect us, it could restrict options for smaller competitors if the number of available contract manufacturers decreases," he stated during a media call following Roche's quarterly sales report.
Consumer advocacy groups and labor unions recently petitioned the U.S. Federal Trade Commission (FTC) to intervene against the acquisition, citing risks to competition in the market for weight loss drugs and advanced gene therapies. They argued that the deal could limit opportunities for rivals like Amgen, Pfizer, Roche, and AstraZeneca, all of whom are developing obesity treatments, some based on complex peptides.
Other companies, such as Viking Therapeutics, Structure Therapeutics, and Sun Pharma, could also be impacted by this acquisition.
In contrast, Novo Holdings has defended its position, asserting a "pro-competitive rationale" for the deal. Teresa Graham, head of Roche's pharmaceutical division, reassured stakeholders that Roche is well-prepared, stating, "We have secured capacity with other contract manufacturing organizations and are confident in our production capabilities."
Roche plans to utilize a combination of in-house and external manufacturing for its forthcoming obesity drug launches, ensuring a steady supply chain.
